Despite promising early data, the company struggled to stand out in a competitive ophthalmology environment. Awareness among retinal specialists was limited, clinical communications lacked coherence, and advocacy from opinion leaders was insufficient to influence enrollment or investor perception. The absence of a scalable HCP engagement model left the organization without the momentum required to command strong acquisition interest.

We designed and implemented a focused HCP and KOL engagement strategy that elevated the company’s presence among key retinal investigators. The clinical value story was clarified and communicated consistently to external stakeholders, highlighting mechanism differentiation and patient relevance. Trial visibility improved as strategic touchpoints with investigators increased, and the internal narrative used for scientific, clinical, and corporate discussions was unified under a single framework. The result was an integrated communication infrastructure that supported enrollment, strengthened credibility, and positioned the asset more competitively in the retinal innovation space.